ZYNLONTA™ (loncastuximab tesirine-lpyl) is an antibody-drug conjugate (ADC) used in cancer treatment. It combines an antibody, which specifically targets a protein called CD19 on cancer cells, with a powerful chemotherapy drug that kills the cancer cells.
Loncastuximab Tesirine-lpyl
Generic Name/API:Loncastuximab Tesirine-lpyl
Packaging:Single-dose vial.
Storage:2°C to 8°C (36°F to 46°F)
Dosage: ZYNLONTA as an intravenous infusion administered over 30 minutes on Day 1 of each cycle (every 3 weeks). Administer intravenous infusion as follows: 0.15 mg/kg every 3 weeks for 2 cycles. 0.075 mg/kg every 3 weeks for subsequent cycles.
Strength:For injection: 10 mg of loncastuximab tesirine-lpyl as a lyophilized powder in a single-dose vial for reconstitution and further dilution.
Indication:ZYNLONTA is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.
ZYNLONTA (Loncastuximab Tesirine) is an innovative antibody-drug conjugate (ADC) representing a targeted approach in cancer therapy. It is specifically designed to deliver a potent chemotherapy agent directly to cancerous B-cells by targeting CD19, a protein found on the surface of most B-cell lymphomas. Approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from low-grade lymphoma, after two or more lines of systemic therapy
STRENGTH:
For injection: 10 mg of loncastuximab tesirine-lpyl as a lyophilized powder in a single-dose vial for reconstitution and further dilution.
DOSAGE:
ZYNLONTA as an intravenous infusion administered over 30 minutes on Day 1 of each cycle (every 3 weeks). Administer intravenous infusion as follows: 0.15 mg/kg every 3 weeks for 2 cycles. 0.075 mg/kg every 3 weeks for subsequent cycles.
ADVERSE EFFECTS:
- Effusion and Edema
- Myelosuppression
- Infections
- Cutaneous Reactions
STORAGE:
2°C to 8°C (36°F to 46°F)
- Effusion and Edema
Serious effusion and edema occurred in patients treated with ZYNLONTA. Grade 3 edema occurred in 3% (primarily peripheral edema or ascites) and Grade 3 pleural effusion occurred in 3% and Grade 3 or 4 pericardial effusion occurred in 1% . Monitor patients for new or worsening edema or effusions. Withhold ZYNLONTA for Grade 2 or greater edema or effusion until the toxicity resolves.
- Myelosuppression
Treatment with ZYNLONTA can cause serious or severe myelosuppression, including neutropenia, thrombocytopenia, and anemia. Grade 3 or 4 neutropenia occurred in 32%, thrombocytopenia in 20%, and anemia in 12% of patients.
- Infections Fatal and serious infections, including opportunistic infections,
occurred in patients treated with ZYNLONTA. Grade 3 or higher infections occurred in 10% of patients, with fatal infections occurring in 2%. The most frequent Grade ≥3 infections included sepsis and pneumonia
- Embryo-Fetal Toxicity Based on its mechanism of action,
ZYNLONTA can cause embryo-fetal harm when administered to a pregnant woman because it contains a genotoxic compound (SG3199) and affects actively dividing cells. Advise pregnant women of the potential risk to a fetus.
FAQ
What type of cancer is ZYNLONTA™ used to treat?
ZYNLONTA™ is approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from low-grade lymphoma, who have received two or more prior lines of systemic therapy. “Relapsed” means the cancer has returned after treatment, and “refractory” means the cancer did not respond to previous treatments.
How does ZYNLONTA™ work?
ZYNLONTA™ works by targeting CD19, a protein commonly found on the surface of B-cell lymphoma cells. Once the antibody part of ZYNLONTA™ binds to CD19 on a cancer cell, the entire ADC is absorbed into the cell. Inside the cancer cell, the chemotherapy drug (tesirine) is released, causing DNA damage and leading to the death of the cancerous cell.
What are the common side effects of ZYNLONTA™?
Common side effects can include fatigue, rash, nausea, musculoskeletal pain, edema (swelling), peripheral neuropathy, decreased appetite, and liver enzyme elevations (transaminase elevation). It’s important to discuss all potential side effects and any concerns with your healthcare team.
Who should not take ZYNLONTA™ or use it with caution?
ZYNLONTA™ may not be suitable for everyone. Patients who have had a severe allergic reaction to loncastuximab tesirine-lpyl or any of its components should not take it. Caution may be advised for patients with pre-existing severe skin conditions, severe fluid accumulation (effusions), or significant liver problems. Always inform your doctor about your complete medical history and all medications you are taking.
What is the cost of Zynlonta (Loncastuximab-tesirine-lpyl) in India?
The cost of zynlonta (loncastuximab-tesirine-lpyl) in India varies as it is not locally approved and must be imported. Supplier availability, import duties, and currency fluctuations affect the final price. For the latest cost details, contact 24/7QualityMeds at +91 9967979080.
How to buy zynlonta (loncastuximab-tesirine-lpyl) injection online in India
To buy zynlonta (loncastuximab-tesirine-lpyl) injection in India at a genuine price, contact 24/7QualityMeds. We assist with legal import procedures, sourcing from certified suppliers, and ensuring safe delivery.
What are the key criteria for selecting a supplier?
While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) certificate and possesses a valid operating license. These credentials confirm that the suppliers adherence to International standards for the proper distribution of medicinal product.
